G1 Therapeutics is currently enrolling a multi-center, open-label study of the safety and efficacy of an investigational medicine for patients with Stage IV metastatic Triple Negative Breast Cancer (TNBC). 

To qualify for the study patients will only be permitted to have had up to 1 prior chemotherapy regimen. Also, prior treatment with adjuvant/neoadjuvant (tumor removal) chemotherapy is allowed if at least 12 months have passed since last chemotherapy administration and recurrence of disease.